Company Description
Apimeds Pharmaceuticals US is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects.
Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since 2003 and now we will be pursuing a second Phase III trial to meet agreed upon FDA standards.
Upon the successful completion of our Phase III trial demonstrating therapeutic effect and extended safety data for the use of Apitox to treat pain and mobility in patients with knee OA, we intend to submit a Biologics License Application for Apitox.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Erik Emerson |
Contact Details
Address: 2 East Broad Street 2nd Floor Hopewell, NJ 08425 United States | |
| Phone | 925-872-6429 |
| Website | apimedsus.com |
Stock Details
| Ticker Symbol | APUS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001894525 |
| Employer ID | 85-1099700 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher Kim, MD | Chairman and Chief Medical Officer |
| Erik Emerson | Chief Executive Officer and Chief Financial Officer |
| Jakap Koo | Director |
| Dr. Bennett Weintraub, PhD. | Director |
| Hankil Yoon | Director |
| Carol O’Donnell | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 4, 2025 | CERT | Certification by an exchange approving securities for listing |
| Mar 3, 2025 | 8-A12B | Registration of securities |
| Feb 11, 2025 | EFFECT | Notice of Effectiveness |
| Feb 10, 2025 | FWP | Free Writing Prospectus |
| Feb 10, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 7, 2025 | UPLOAD | Filing |
| Feb 6, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 29, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 10, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |